Biotech grants in Switzerland

Closed

Pays up to 25 small consortia EUR 200,000 each to test the commercial exploitation potential of results that already came out of earlier Horizon Europe or Horizon 2020 Cluster 4 projects.

Funds clinical trials of prophylactic vaccines against neglected tropical diseases such as schistosomiasis, leishmaniasis and leprosy in sub-Saharan Africa.

Closed

Pays deep-tech start-ups, SMEs and research organisations a €300,000 lump sum in Stage 1, then up to €2.5 million in Stage 2, to push high-risk breakthrough innovations that lack commercial uptake toward real-world, demand-tested deployment.

Closed

Funds early clinical trials of therapies built from the molecules cells secrete rather than the cells themselves, aiming for an off-the-shelf alternative to cell therapy.

Funds research into biomanufactured alternatives to imported natural rubber and fossil-based synthetic rubber for automotive, healthcare and industrial uses.

Funds research into bio-based, biodegradable delivery coatings for fertilisers that replace today's microplastic-shedding polymer coatings.

Funds a full-scale biorefinery that produces bio-based drop-in platform chemicals able to compete directly with their fossil-based equivalents.

Closed

Pays 200,000 euros to study bioengineering business ideas that use microgravity.

Closed

Funds biodiscovery projects that use AI and digital tools to find and sustainably produce new natural compounds from marine and freshwater organisms.

Closed

Funds companies discovering and scaling up bioactive natural compounds from land-based organisms for pharma, cosmetics, food and other markets.

Closed

Funds biotechnology and monitoring tools that remove persistent contaminants from marine, freshwater and groundwater systems.

Closed

Funds early-stage research teams developing climate-resilient crops and plant-based biomanufacturing of high-value nutrients.

Closed

Funds small, SME-majority consortia running an early-phase clinical trial to move a biotech therapy, from antibodies to RNA therapies, from the lab towards the market.

Closed

Pays three European consortia EUR 15 million each to run generative-AI competitions in aerospace, pharma or telecoms, re-granting up to EUR 2 million per finalist SME team that competes.

Funds a full-scale plant scaling up fibre-based packaging with new or improved properties, designed from the start for recycling or reuse.

Funds converting a batch biotech process for making bio-based chemicals or materials into a continuous process with higher productivity and lower cost.

Pays a university-industry network to build and test new training curricula for bioeconomy skills like biomanufacturing, ecodesign and circularity.

Closed

Funds research teams that use gene and epigenome editing to engineer safer, more effective off-the-shelf cell therapies for one chosen disease area.

Closed

Funds bio-based and nature-based remediation projects that clean up polluted soil, sediment and water.

Closed

Pays one coordination team to run the EU-wide policy forum that gets governments, regulators and industry to agree on which animal-testing-alternative methods are ready for official use.

Closed

Funds the coordination of up to ten existing advanced-therapy research centres into one European network, with a shared roadmap for scaling up gene and cell therapy manufacturing.

Closed

Funds a pan-European network of 10-18 startup and scaleup hubs that can pass on up to EUR 60,000 per deep-tech startup for cross-border scaling support.

Closed

Funds the next development stage, TRL 5 and up, for regenerative-medicine results that already came out of an earlier, completed EU-funded research project.

Closed

Funds consortia that build or adapt generative AI models on large-scale multimodal health data and prove their value with at least two real biomedical use cases.